Strides Arcolab hives off research, R&D divisions

has joined the likes of leading drug firms such as Dr Reddy’s, and Glenmark by hiving off its research and speciality divisions to de-risk its core businesses.

The company today announced a corporate reorganisation that will see its businesses being split into three entities – speciality pharmaceuticals, pharmaceuticals and research and development.

The process will involve its specialty pharma business and research and development becoming wholly-owned subsidiaries, Strides Specialities Pvt Ltd and Strides Technology and Research Pvt Ltd, respectively. The pharma business will continue under the parent company.

Strides had annual revenues of Rs 1,377 crore in 2008, the bulk of which came from its pharma business. The company share price rose 6.9 per cent to close at Rs 105.6 on the BSE today.

The reorganisation will see four of its Indian subsidiaries being merged with the parent company. “Strides has about 40 subsidiaries globally. The restructuring will see several of these being merged into the three major entities. This will allow us to go for strategic sourcing and realignment at the international level for optimisation of our capabilities,” said a company official.

“The reorganisation is a major step to attain greater efficiency and accountable, customer-focused business units, while still retaining the aggressive and entreprenerual spirit of Strides. Both our business units will be backed by a strong and independent R&D function,” said Group CEO Arun Kumar.

The R&D entity of Strides expects to generate its own revenues through in-licensing and out-licensing deals, company officials said. “We have a huge pipeline of research products. Hiving off our R&D business can unlock that value,” they added.

In a separate development, the Strides board today decided to issue 6.2 million preferential shares worth Rs 60 crore in current market value to meet ongoing corporate expenses. Company officials described the fund raising plan as ‘routine’.

image
Business Standard
177 22
Business Standard

Strides Arcolab hives off research, R&D divisions

BS Reporter  |  Bangalore 

has joined the likes of leading drug firms such as Dr Reddy’s, and Glenmark by hiving off its research and speciality divisions to de-risk its core businesses.

The company today announced a corporate reorganisation that will see its businesses being split into three entities – speciality pharmaceuticals, pharmaceuticals and research and development.

The process will involve its specialty pharma business and research and development becoming wholly-owned subsidiaries, Strides Specialities Pvt Ltd and Strides Technology and Research Pvt Ltd, respectively. The pharma business will continue under the parent company.

Strides had annual revenues of Rs 1,377 crore in 2008, the bulk of which came from its pharma business. The company share price rose 6.9 per cent to close at Rs 105.6 on the BSE today.

The reorganisation will see four of its Indian subsidiaries being merged with the parent company. “Strides has about 40 subsidiaries globally. The restructuring will see several of these being merged into the three major entities. This will allow us to go for strategic sourcing and realignment at the international level for optimisation of our capabilities,” said a company official.

“The reorganisation is a major step to attain greater efficiency and accountable, customer-focused business units, while still retaining the aggressive and entreprenerual spirit of Strides. Both our business units will be backed by a strong and independent R&D function,” said Group CEO Arun Kumar.

The R&D entity of Strides expects to generate its own revenues through in-licensing and out-licensing deals, company officials said. “We have a huge pipeline of research products. Hiving off our R&D business can unlock that value,” they added.

In a separate development, the Strides board today decided to issue 6.2 million preferential shares worth Rs 60 crore in current market value to meet ongoing corporate expenses. Company officials described the fund raising plan as ‘routine’.

RECOMMENDED FOR YOU

Strides Arcolab hives off research, R&D divisions

Strides Arcolab Ltd has joined the likes of leading drug firms such as Dr Reddy’s, Piramal Healthcare and Glenmark by hiving off its research and speciality divisions to de-risk its core businesses.

has joined the likes of leading drug firms such as Dr Reddy’s, and Glenmark by hiving off its research and speciality divisions to de-risk its core businesses.

The company today announced a corporate reorganisation that will see its businesses being split into three entities – speciality pharmaceuticals, pharmaceuticals and research and development.

The process will involve its specialty pharma business and research and development becoming wholly-owned subsidiaries, Strides Specialities Pvt Ltd and Strides Technology and Research Pvt Ltd, respectively. The pharma business will continue under the parent company.

Strides had annual revenues of Rs 1,377 crore in 2008, the bulk of which came from its pharma business. The company share price rose 6.9 per cent to close at Rs 105.6 on the BSE today.

The reorganisation will see four of its Indian subsidiaries being merged with the parent company. “Strides has about 40 subsidiaries globally. The restructuring will see several of these being merged into the three major entities. This will allow us to go for strategic sourcing and realignment at the international level for optimisation of our capabilities,” said a company official.

“The reorganisation is a major step to attain greater efficiency and accountable, customer-focused business units, while still retaining the aggressive and entreprenerual spirit of Strides. Both our business units will be backed by a strong and independent R&D function,” said Group CEO Arun Kumar.

The R&D entity of Strides expects to generate its own revenues through in-licensing and out-licensing deals, company officials said. “We have a huge pipeline of research products. Hiving off our R&D business can unlock that value,” they added.

In a separate development, the Strides board today decided to issue 6.2 million preferential shares worth Rs 60 crore in current market value to meet ongoing corporate expenses. Company officials described the fund raising plan as ‘routine’.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard